Cardenilimab Combined With Chemotherapy

Phase 2Small molecule

Cardenilimab Combined With Chemotherapy is one of 47 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

241 competitors in Esophageal Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

30 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

31 3

Keytruda

Merck & Co.

Phase 3

8 4

Imfinzi

AstraZeneca

Phase 3

4 5

Eloxatin

Teva

Phase 3

4 6

Tecentriq

Roche

Phase 3

2 7

Opdivo

Bristol-Myers Squibb

Phase 3

2 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

9 9

Taxotere

AAvyxa

Phase 3

8 10

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Esophageal Squamous Cell Carcinoma

NCT06165380

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

A Prospective, Multicenter, Phase II Study on the Efficacy and Safety of Cardenilimab Combined With Chemotherapy in the Conversion Therapy of Locally Advanced Esophageal Squamous Cell Carcinoma.

Active, not recruiting·LLi Zhang·Phase 2·NCT06165380·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cardenilimab Combined With Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cardenilimab Combined With Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cardenilimab Combined With Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Li Zhang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLi Zhang

Cardenilimab Combined With Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News